BioNexus Gene Lab Corp (NASDAQ:BGLC) traded at $0.37 at close of the session on current trade day and made an upward move of 1.14% on its previous day’s price.
Looking at the stock we see that its previous close was $0.36 and the beta (5Y monthly) reads 1.866 with the day’s price range being $0.322 – $0.46. In terms of its 52-week price range, BGLC has a high of $3.39 and a low of $0.21. The company’s stock has gained about 21.70% over that past 30 days.
BioNexus Gene Lab Corp has a market cap of $6.56 million and is expected to release its quarterly earnings report in February.
On the other hand, looking at the outlook for the BGLC stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 50% Sell.
Looking further, we note the current price level is 25.60% off its SMA20 and 18.13% from its 50-day simple moving average. The RSI (14) is pointing at 58.24 while the volatility over the past week is 67.49% and jumps to 25.21% over the past one month. The beta value is 1.61, while the average true range (ATR) is currently pointing at 0.09.
Coming back to BioNexus Gene Lab Corp (NASDAQ:BGLC), we note that the average 3-month trading volume was 3.85 million, while that of the preceding 10-day period stands at 20.98 million. Current shares outstanding are 17.97 million.
The insiders hold 34.82% of the company’s shares while institutions hold 0.73%. The data shows that short shares as of 2024-10-31, stood at 0.14 million at a short ratio of 2.21. This represents a 80.00 short interest in shares outstanding on 2024-10-31. Shares short fall in October from the previous month at 0.19 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 30.53% up in year-to-date price movement.
